Tumor-mediated immunosuppression and cytokine spreading affects the relation between EMT and PD-L1 status

Front Immunol. 2023 Aug 10:14:1219669. doi: 10.3389/fimmu.2023.1219669. eCollection 2023.

Abstract

Epithelial-mesenchymal transition (EMT) and immune resistance mediated by Programmed Death-Ligand 1 (PD-L1) upregulation are established drivers of tumor progression. Their bi-directional crosstalk has been proposed to facilitate tumor immunoevasion, yet the impact of immunosuppression and spatial heterogeneity on the interplay between these processes remains to be characterized. Here we study the role of these factors using mathematical and spatial models. We first designed models incorporating immunosuppressive effects on T cells mediated via PD-L1 and the EMT-inducing cytokine Transforming Growth Factor beta (TGFβ). Our models predict that PD-L1-mediated immunosuppression merely reduces the difference in PD-L1 levels between EMT states, while TGFβ-mediated suppression also causes PD-L1 expression to correlate negatively with TGFβ within each EMT phenotype. We subsequently embedded the models in multi-scale spatial simulations to explicitly describe heterogeneity in cytokine levels and intratumoral heterogeneity. Our multi-scale models show that Interferon gamma (IFNγ)-induced partial EMT of a tumor cell subpopulation can provide some, albeit limited protection to bystander tumor cells. Moreover, our simulations show that the true relationship between EMT status and PD-L1 expression may be hidden at the population level, highlighting the importance of studying EMT and PD-L1 status at the single-cell level. Our findings deepen the understanding of the interactions between EMT and the immune response, which is crucial for developing novel diagnostics and therapeutics for cancer patients.

Keywords: PD-L1; cellular Potts model; epithelial-mesenchymal transition (EMT); immunoevasion; ordinary differential equations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen*
  • Cytokines
  • Epithelial-Mesenchymal Transition
  • Humans
  • Immunosuppression Therapy
  • Neoplasms*
  • Transforming Growth Factor beta

Substances

  • CD274 protein, human
  • B7-H1 Antigen
  • Cytokines
  • Transforming Growth Factor beta

Grants and funding

This work was supported by a Vidi grant from the Netherlands Organization for Scientific Research (NWO; grant 864.12.013 to JB).